POC

Global IoT eSIM Market Growth Opportunities Report, Featuring Profiles of IoT eSIM Providers - Thales, G+D, IDEMIA, Valid, Kigen, Oasis Smart SIM and Workz - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Technology, IOT (Internet of Things), POC, Internet of things, ESIM, Electrospray, SIM, RSP, GSMA, Mobile phone

The "Global IoT eSIM Market Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global IoT eSIM Market Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The global IoT eSIM market is at an early stage, with providers collaborating to standardize the technology.
  • Most cellular IoT devices connect to physical SIM cards, while the rest incorporate eSIMs for testing and proof of concept (PoC).
  • Once providers standardize IoT eSIM technology, the market is forecast to grow quickly.

InnoCare Releases 2023 Results and Business Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, QD, Tafasitamab, Patient, B-cell lymphoma, NDA, SLE, POC, IND, Clinical trial, Bone marrow, IKZF1, Phase, Therapy, IGA, MCD, Dexamethasone, MCL, Neuromyelitis optica spectrum disorder, IKZF3, AML, NMOSD, Outline of health sciences, DLT, Cancer, Autoimmune disease, Safety, TYK2, HSA, NRDL, BLA, Follicular lymphoma, Food, GC, Development, Multiple sclerosis, PD, CRBN, Public, Gordon Ramsay's Bank Balance, Multiple myeloma, ITP, BCL2, Leukemia, Cmax, Gadolinium, HKEX, SRI, AAD, Proteinuria, DLBCL, Glucocorticoid, IVIG, Loss, European Hematology Association, American Academy, EHA, Lenalidomide, NHL, Non-Hodgkin lymphoma, CCR8, US FDA, BTK, NRS, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
  • In 2023, InnoCare has continued to advance its robust pipeline across various clinical stages, continuously unleashing the power of innovation to meet unmet medical needs.
  • In June 2023, the ITP Phase II result was orally presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • InnoCare was approved by the Hong Kong Stock Exchange to remove "B" from the stock code from May 12, 2023.

3EO Health Announces the First Point of Care Molecular Test Under $15

Retrieved on: 
Thursday, March 28, 2024
Science, Other Science, Biotechnology, Medical Supplies, General Health, Health, COVID-19, Health Technology, Patient, Acquisition, Workflow, POC, Multimedia, Physician, Family, Work, Perfusion

3EO Health , a “Point of Life” diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable.

Key Points: 
  • 3EO Health , a “Point of Life” diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable.
  • View the full release here: https://www.businesswire.com/news/home/20240327647032/en/
    3EO high efficiency molecular 3TR technology enables testing to be executed in multiple settings and locations.
  • With a cost per test up to 70% lower than existing technologies, 3EO is seeking to create access to molecular technology for more physicians and consumers by providing molecular POC tests under $15.
  • 3EO Health received EUA authorization for its COVID-19 test utilizing 3TR technology in Q4 of 2023.

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Retrieved on: 
Monday, March 25, 2024
Technology, Neurology, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Artificial Intelligence, Survival, Verge, ALS, Caregiver, Social justice, Partnership, Patient, Tissue, News, Ferrer, POC, Neuron, B Corporation (certification), Clinical trial, Genomics, DSM-IV codes, Drug development, Safety, Pharmaceutical industry

VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.

Key Points: 
  • VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.
  • Under the terms of the agreement, Ferrer will obtain the exclusive rights to co-develop and commercialize VRG50635 for ALS in multiple regions outside of the United States of America.
  • Verge has retained all rights to development and commercialization for VRG50635 for all uses in the United States and all countries outside the agreement.
  • “We're thrilled to work with Ferrer to progress VRG50635 through clinical development and towards potential commercialization.

NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, General Health, Other Health, Health, Medical Supplies, College, Growth, Thomas Jefferson University, OraSure Technologies, HIV, Business, University, COVID-19, Syphilis, Research, History, Humanities, MBA, OTC, POC, Chemical engineering, Multimedia, Lehigh University, FDA, University City Science Center, Population Services International, Management

NOWDiagnostics ( NOWDx ), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company’s board of directors.

Key Points: 
  • NOWDiagnostics ( NOWDx ), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company’s board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20240321747977/en/
    NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire)
    Dr. Tang is a longtime veteran of the medical diagnostic industry.
  • He led OraSure Technologies, Inc. (NASDAQ: OSUR ), a pioneer and global leader in rapid at-home tests for HIV and COVID-19, for ten years as president and CEO, chairman of the board of directors, and chairman of the compensation committee.
  • “I am delighted and enthusiastic about joining the NOWDx team as their chairman of the board,” said Dr. Tang.

Datricks Empowers FORVIA HELLA to Automate Risk Detection for Business Process Transformation Leveraging SAP Signavio Solutions

Retrieved on: 
Wednesday, March 20, 2024
Software, Professional Services, Fintech, Data Management, General Automotive, Technology, Automotive, Security, Automotive Manufacturing, Finance, Other Automotive, Manufacturing, Process management, Internal control, Organization, Software as a service, Risk management, Risk, Acceleration, Signavio, Partnership, SAP, POC, Lead, Mining

Utilizing the SAP Signavio portfolio, this strategic collaboration showcases Datricks' commitment to delivering cutting-edge, data-driven risk detection and mitigation solutions.

Key Points: 
  • Utilizing the SAP Signavio portfolio, this strategic collaboration showcases Datricks' commitment to delivering cutting-edge, data-driven risk detection and mitigation solutions.
  • SAP Signavio is a leading solution suite in the business process transformation space.
  • Integrating with the SAP Signavio suite, Datricks’ solution will empower FORVIA HELLA to unlock the potential of transactional integrity, aligning with the company’s acceleration and process transformation program.
  • Leveraging the integration with SAP Signavio, Datricks’ solution empowers FORVIA HELLA to automate risk identification and mitigation across processes and source systems, providing comprehensive insights into risk posture and process weaknesses.

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bioreactor, Malignancy, Cell, Chemistry, Patient, Orphan, Good manufacturing practice, Health care, CMC, G&A, Molecular biology, Quality of life, European Medicines Agency, Science, Clinical trial, Cisplatin, Therapy, Hertz, Neoplasm, CIO, Congress, Huber loss, Partnership, Ageing, EMA, Hearing loss, GMP, Cochlea, Biochemistry, Safety, Language, Perilymph, G7, Medication, Control, AAV, PTA, IHC, Pasteur Institute, CDMO, Communication, Genetics, Research, KOL, Ear, POC, FDA, Ototoxicity, GJB2, ABR, CTA, ANSM, Audiogram, Platinum, Investment company, Congenital hearing loss, Pathology, Presbycusis, Hearing, Pharmaceutical industry

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.

AECC and GSMA Intelligence to Lead Webinar “Edge: Coming to a Place Near You”

Retrieved on: 
Wednesday, March 13, 2024
Automotive Manufacturing, Manufacturing, Education, Other Consumer, Electronic Commerce, Consumer, Mobile, Wireless, Other Construction & Property, Other Retail, IOT (Internet of Things), Construction & Property, Other Communications, Other Transport, Communications, Transport, Telecommunications, Retail, Software, Networks, Internet, Science, Hardware, Data Management, Consumer Electronics, Automotive, Technology, Other Energy, Other Science, Satellite, Green Technology, Research, Audio, Video, Environment, Energy, Other Education, Denso, Organization, Development, Internet of things, Opening Remarks, POC, Pocs, Investment, AECC, Ecosystem, Research report, Intelligence, GSMA, Renewable energy

The Automotive Edge Computing Consortium ( AECC ), has issued an open invitation to its upcoming Mobile World Live webinar, “ Edge: Coming to a Place Near You .” The free event takes place on Tuesday, March 26 at noon Eastern and advanced registration is required.

Key Points: 
  • The Automotive Edge Computing Consortium ( AECC ), has issued an open invitation to its upcoming Mobile World Live webinar, “ Edge: Coming to a Place Near You .” The free event takes place on Tuesday, March 26 at noon Eastern and advanced registration is required.
  • The AECC and GSMA Intelligence recent report evaluates edge investment sentiment, challenges, costs and opportunities for edge computing.
  • The research reveals a robust expansion in the demand for edge computing, primarily fueled by enterprises undergoing digital transformation.
  • Attendees will learn about key findings from the AECC and GSMA research report on the state of edge computing, including:
    A look at the rising market demand for edge computing.

NTT to Host Upgrade 2024 Global Research & Innovation Summit

Retrieved on: 
Monday, March 11, 2024
Technology, Security, Other Technology, Health Technology, Software, Networks, Internet, Health, Data Management, IOT (Internet of Things), Pixar, Wireless network, PHI, Information, POC, LLM, The Walt Disney Company, Reality, Photosynthesis, Research, Microsoft, Instrument, MEI, Lucasfilm, CO2, Master of ceremonies, Privacy, Metreon, Physics, Climate change, Luhn algorithm, Intelligence, Nippon Telegraph and Telephone, NTT Data, AI, Student, TFLN, Sustainability, Machine learning, CIS, Data wrangling, Public sector, APN, Cloud computing, NTT, Ecosystem, DARPA, Mobile phone

NTT Research, Inc. , a division of NTT (TYO:9432), today announced plans to hold Upgrade 2024 , NTT’s Global Research & Innovation Summit, on April 10-11, 2024.

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced plans to hold Upgrade 2024 , NTT’s Global Research & Innovation Summit, on April 10-11, 2024.
  • Day 2 (April 11) of Upgrade 2024 will kick-off at the Metreon with remarks by NTT Research President Gomi.
  • The second, on basic research, features NTT Venture Capital (VC) Founding Partner Vab Goel, NTT Senior Executive Vice President CTO Katsuhiko Kawazoe and NTT Research President Gomi.
  • NTT Research invites business leaders, students, academics, researchers and journalists to attend, as well as NTT customers, employees, partners and stakeholders.

Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation

Retrieved on: 
Monday, March 11, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Genetics, Clinical Trials, Cochlear Limited, Cochlear, Patient, Cochlea, POC, Perilymph, Huber loss, Data, Hearing, Physician, Medical device

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces it has met the primary endpoint for its Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation.

Key Points: 
  • Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces it has met the primary endpoint for its Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for residual hearing preservation following cochlear implantation.
  • The study has been developed in collaboration with Cochlear Limited (Cochlear), the global leader in implantable hearing devices.
  • On February 1, 2024, Sensorion announced the completion of patient inclusion in the Phase 2a clinical trial of SENS-401 for the residual hearing preservation after cochlear implantation.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: "We are delighted to announce we met the primary endpoint for the Phase 2a clinical trial of SENS-401 for residual hearing preservation.